Regenerative Medicine

Regenerative Medicine英文簡(jiǎn)介

Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization.

Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community.

Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

Regenerative Medicine中文簡(jiǎn)介

《Regenerative Medicine》是一本由FUTURE MEDICINE LTD出版商出版的專業(yè)醫(yī)學(xué)期刊，該刊創(chuàng)刊于2006年，刊期Bimonthly，該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄。在中科院最新升級(jí)版分區(qū)表中，該刊分區(qū)信息為大類學(xué)科：工程技術(shù) 4區(qū)，小類學(xué)科：細(xì)胞與組織工程 4區(qū)；工程：生物醫(yī)學(xué) 4區(qū)；在JCR（Journal Citation Reports）分區(qū)等級(jí)為Q3。該刊發(fā)文范圍涵蓋細(xì)胞與組織工程等領(lǐng)域，旨在及時(shí)、準(zhǔn)確、全面地報(bào)道國(guó)內(nèi)外細(xì)胞與組織工程工作者在該領(lǐng)域取得的最新研究成果、工作進(jìn)展及學(xué)術(shù)動(dòng)態(tài)、技術(shù)革新等，促進(jìn)學(xué)術(shù)交流，鼓勵(lì)學(xué)術(shù)創(chuàng)新。2021年影響因子為3.21，平均審稿速度較慢,6-12周。

中科院分區(qū)最新升級(jí)版（當(dāng)前數(shù)據(jù)版本：2021年12月最新升級(jí)版）

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)	Top期刊	綜述期刊
工程技術(shù)	4區(qū)	CELL & TISSUE ENGINEERING 細(xì)胞與組織工程 ENGINEERING, BIOMEDICAL 工程：生物醫(yī)學(xué)	4區(qū) 4區(qū)	否	否

JCR分區(qū)（當(dāng)前數(shù)據(jù)版本：2021-2022年最新版）

JCR分區(qū)等級(jí)	JCR所屬學(xué)科	分區(qū)	影響因子
Q3	ENGINEERING, BIOMEDICAL	Q3	3.21
	CELL & TISSUE ENGINEERING	Q4

期刊指數(shù)

影響因子	h-index	Gold OA文章占比	研究類文章占比	OA開放訪問(wèn)	平均審稿速度
3.21	53	21.03%	56.34%	未開放	較慢,6-12周

IF值(影響因子)趨勢(shì)圖